Advertisement

Transcutaneous Oxygen Pressure at Different Dosages of Intravenous Prostaglandin E1 in Patients with Severe Arterial Occlusive Disease: A Double-Blind, Placebo-Controlled Study

  • A. Creutzig
  • L. Caspary
  • K. Alexander
Conference paper

Abstract

In patients with advanced stages of peripheral arterial occlusive disease, the increasing perfusion of ischemic skin is of particular therapeutic significance. In several clinical studies [10, 12, 18], an increase in the transcutaneous oxygen pressure could be observed after intravenous prostaglandin Ex infusion. The present study investigated the question of whether the transcutaneous oxygen pressure can also be improved in selected patients with very low pressures and thus a poor initial situation. Moreover, the dose dependency of this parameter was investigated.

Keywords

Intermittent Claudication Arterial Occlusive Disease Peripheral Arterial Occlusive Disease Intraarterial Infusion Skin Microcirculation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alexander K (1975) Gefäßkrankheiten. Steinkopf, Stuttgart, p 75Google Scholar
  2. 2.
    Caspary L, Creutzig A, Alexander K (1987) Reaction of transcutaneous PO2 and laser Doppler flow signal on intraarterial infusion of PGE1 and nucleotide phosphates in patients with peripheral arterial occlusive disease. Vasa Suppl 17: 17–22PubMedGoogle Scholar
  3. 3.
    Caspary L, Creutzig A, Alexander K (1988) Wirkung intraarterieller Infusionen auf den VorfuB tcPO2 bei Patienten mit arterieller Verschlußkrankheit. Vasa Suppl 23: 54–56Google Scholar
  4. 4.
    Creutzig A, Caspary L, Alexander K (1987) Transcutaneous oxygen pressure measured at two different electrode core temperatures in healthy volunteers and patients with arterial occlusive disease. Int J Microcirc Clin Exp 5: 373–378PubMedGoogle Scholar
  5. 5.
    Creutzig A (1991) Evaluation of pharmacologic effects. In: Belcaro G, Bollinger A, Nicolaides AN, Hoffmann U (eds) Progress in the evaluation of the microcirculation by laser Doppler flowmetry. Med Orion, London (in press)Google Scholar
  6. 6.
    Creutzig A, Caspary L, Alexander K (1990) Skin surface oxygen pressure fields during administration of prostaglandin E1 in patients with arterial occlusive disease. Klin Wochenschr 68: 207–212PubMedCrossRefGoogle Scholar
  7. 7.
    Creutzig A, Caspary L, Alexander K (1991) Skin surface oxygen pressure in healthy volunteers and patients with arterial occlusive disease. Int J Microcirc Clin Exp 10: 231–240PubMedGoogle Scholar
  8. 8.
    Creutzig A, Caspary L, Ranke C, Kiessling D, Wilkens J, Frölich J, Alexander K (1987) Transkutaner PO2 and Laser Doppler Flux bei steigenden Dosierungen von intraarteriell und intravenös appliziertem Prostaglandin E1. Vasa 16: 114–118PubMedGoogle Scholar
  9. 9.
    Creutzig A, Lux M, Alexander K (1984) Muscle tissue oxygen pressure fields and transcutaneous oxygen pressure in healthy men during intra-arterial prostaglandin E1 infusion. Int Angiol 3: 105–110Google Scholar
  10. 10.
    Ehrly AM, Schenk J, Saeger-Lorenz K (1987) Einfluß einer intravenösen Gabe von Prostaglandin E1 auf den Muskelgewebesauerstoffdruck, die transkutanen Gasdruckwerte und die Fließeigenschaften des Blutes von Patienten im Stadium III und IV der chronischen arteriellen Verschlußkrankheit. Vasa Suppl 20: 196–198Google Scholar
  11. 11.
    Fagrell B, Lundberg G, Olsson A, Östergren J (1986) PGE1 treatment of severe skin ischemia in patients with peripheral insufficiency - the effect on skin microcirculation. Vasa 15: 56–60PubMedGoogle Scholar
  12. 12.
    Heidrich H, Lammersen T (1985) Vitalkapillarmikroskopische Untersuchungen und transkutane PO2-Messungen bei intravenoser Prostaglandin-E1-Infusion. Dtsch Med Wochenschr 110: 1283–1285PubMedCrossRefGoogle Scholar
  13. 13.
    Jogestrand T, Olsson AG (1985) The effect of intravenous prostaglandin E1 in ischaemic pain and on leg blood-flow in subjects with peripheral artery disease: a double-blind controlled study. Clin Physiol 5: 495–502PubMedCrossRefGoogle Scholar
  14. 14.
    Ranke C, Creutzig A, Alexander K (1991) Hämodynamische Effekte einer intermittierenden intraarteriellen Infusionsbehandlung mit Prostaglandin E1 bei peripherer arterieller Verschlußkrankheit. Med Klin 86: 349–352Google Scholar
  15. 15.
    Rieger H, Scheffler A (1987) Fluoreszenzangiographische Befunde nach intravenoser und intraarterieller Infusion von Prostaglandin E1(PGE1) bei Kranken mit arterieller VerschluBkrankheit (AVK) im Stadium II. Vasa Suppl 20: 212–214Google Scholar
  16. 16.
    Rieger H, Scheffler A (1988) Fluoreszenzangiographische Befunde nach intravenoser und intraarterieller Infusion von Prostaglandin E1(PGE1) bei Kranken mit arterieller Verschlußkrankheit (AVK) im Stadium II. In: Heinrich H, Böhme W, Rogatti W (ed) Prostaglandin E1.Wirkungen und therapeutische Wirksamkeit. Springer, Berlin Heidelberg New York, p 66Google Scholar
  17. 17.
    Rudofsky G (1987) Beeinflussung der Kollateralarterien durch i. a.-Prostaglandin E1- Infusion. Vasa Suppl 20: 215–217PubMedGoogle Scholar
  18. 18.
    Scheffler A, Rieger H (1990) Akrale Hautdurchblutungen nach intraarterieller Infusion gefäßerweiternder Substanzen bei Patienten mit Claudicatio intermittens. Med Klin 85: 1–5Google Scholar
  19. 19.
    Scheffler P, De La Hamette D, Leipnitz G (1989) Therapeutic efficacy of intravenously applied prostaglandin E1. Vasa Suppl 28: 19–25PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • A. Creutzig
  • L. Caspary
  • K. Alexander

There are no affiliations available

Personalised recommendations